.jpeg)
2026-05-28 01:55:16
Gilteritinib is a targeted therapy designed for specific genetic mutations.To ensure safety and efficacy,patients must take this medication under the strict supervision of a hematologist or oncologist.Close follow-up and individualized management are essential.In the event of severe adverse reactions,treatment interruption or dose adjustments may be required.
2026-05-27 06:26:35
Pirtobrutinib (Brand Name: Jaypirca) is a next-generation reversible BTK inhibitor offering a new lifeline for patients with relapsed or refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL/SLL). This article details its mechanism against BTK resistance, clinical efficacy, and safety profile.
2026-05-27 05:45:14
Revumenib, a first-in-class oral Menin-MLL1 inhibitor, offers a targeted therapeutic option for acute leukemia patients with KMT2A rearrangements or NPM1 mutations. This article outlines its mechanism of action, management of Differentiation Syndrome, cardiac monitoring protocols, and long-term follow-up strategies for global clinical practice.
2026-05-27 02:05:59
Zongertinib (Hernexeos) gains FDA approval for HER2-mutated NSCLC, offering targeted therapy based on 76% response rate data, transforming treatment landscape.
2026-05-26 04:51:38
A comprehensive analysis of the synergistic mechanisms, global clinical research, safety management, and application of the Ixazomib and Pomalidomide combination for relapsed/refractory multiple myeloma.
2026-05-25 04:22:45
Discover how Etrasimod (Velsipity) works by sequestering lymphocytes to achieve mucosal healing in moderate-to-severe Ulcerative Colitis. Explore its mechanism, efficacy, and future in Crohn's Disease.
2026-05-25 04:15:46
Can topical Delgocitinib (JAK inhibitor) restore skin pigment? Explore the science behind repigmentation, current clinical trial status, and global access for vitiligo patients.
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 05:36:56
Deciphering the dual role of Reactive Oxygen Species (ROS) in cancer, analyzing oxidative stress mechanisms, and exploring the latest research on natural compounds like curcumin in oncology.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
2026-05-22 03:58:23
KOSELUGO® (Selumetinib), a highly selective MEK inhibitor, is now approved for pediatric and adult patients with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This article explores the clinical challenges, dosing strategies, and global market dynamics of this breakthrough targeted therapy.
2026-05-21 06:42:31
Eli Lilly announced FDA approval of Inluriyo (Imlunestrant), an oral estrogen receptor antagonist for ER+, HER2- advanced breast cancer with ESR1 mutations post-endocrine therapy progression.
